Which has better valuation & earnings, PGEN or ABVX?

Precigen has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Precigen $9.68M 273.83 -$250.64M -$1.04 N/A Abivax N/A N/A -$380.27M -$5.21 N/A

Is PGEN or ABVX more profitable?

Abivax has a net margin of 0.00% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Precigen -183.98% 423.75% 84.39% Abivax N/A -99.02% -70.26%

Does the media refer more to PGEN or ABVX?

In the previous week, Abivax had 2 more articles in the media than Precigen. MarketBeat recorded 7 mentions for Abivax and 5 mentions for Precigen. Precigen's average media sentiment score of 1.46 beat Abivax's score of 0.68 indicating that Precigen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PGEN or PRAX?

In the previous week, Precigen had 1 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 5 mentions for Precigen and 4 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.55 beat Precigen's score of 1.46 indicating that Praxis Precision Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor KYMR or PGEN?

In the previous week, Kymera Therapeutics had 4 more articles in the media than Precigen. MarketBeat recorded 9 mentions for Kymera Therapeutics and 5 mentions for Precigen. Precigen's average media sentiment score of 1.46 beat Kymera Therapeutics' score of 0.73 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precigen 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PGEN or IONS?

In the previous week, Ionis Pharmaceuticals had 8 more articles in the media than Precigen. MarketBeat recorded 13 mentions for Ionis Pharmaceuticals and 5 mentions for Precigen. Precigen's average media sentiment score of 1.46 beat Ionis Pharmaceuticals' score of 0.33 indicating that Precigen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ionis Pharmaceuticals 2 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer PGEN or PTGX?

In the previous week, Protagonist Therapeutics had 6 more articles in the media than Precigen. MarketBeat recorded 11 mentions for Protagonist Therapeutics and 5 mentions for Precigen. Precigen's average media sentiment score of 1.46 beat Protagonist Therapeutics' score of 0.65 indicating that Precigen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Precigen (PGEN) Competitors

$7.44 +0.44 (+6.21%)

Closing price 03:59 PM Eastern

Extended Trading

$7.44 0.00 (0.00%)

As of 04:01 PM Eastern

Compare

PGEN vs. ABVX, PRAX, KYMR, IONS, and PTGX

Should you buy Precigen stock or one of its competitors? Precigen's main competitors and comparable companies include Abivax (ABVX), Praxis Precision Medicines (PRAX), Kymera Therapeutics (KYMR), Ionis Pharmaceuticals (IONS), and Protagonist Therapeutics (PTGX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Precigen compare to Abivax?

Precigen (NASDAQ:PGEN) and Abivax (NASDAQ:ABVX) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

Precigen has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	273.83	-$250.64M	-$1.04	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

Precigen currently has a consensus price target of $14.50, indicating a potential upside of 95.02%. Abivax has a consensus price target of $156.38, indicating a potential upside of 52.66%. Given Precigen's higher possible upside, equities research analysts plainly believe Precigen is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

33.5% of Precigen shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 41.4% of Precigen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Abivax has a net margin of 0.00% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-183.98%	423.75%	84.39%
Abivax	N/A	-99.02%	-70.26%

Precigen has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market. Comparatively, Abivax has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

In the previous week, Abivax had 2 more articles in the media than Precigen. MarketBeat recorded 7 mentions for Abivax and 5 mentions for Precigen. Precigen's average media sentiment score of 1.46 beat Abivax's score of 0.68 indicating that Precigen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Precigen beats Abivax on 10 of the 15 factors compared between the two stocks.

How does Precigen compare to Praxis Precision Medicines?

Precigen (NASDAQ:PGEN) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Precigen has a beta of 1.02, indicating that its share price is 2% more volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.76, indicating that its share price is 176% more volatile than the broader market.

Praxis Precision Medicines has a net margin of 0.00% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-183.98%	423.75%	84.39%
Praxis Precision Medicines	N/A	-34.15%	-32.42%

In the previous week, Precigen had 1 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 5 mentions for Precigen and 4 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.55 beat Precigen's score of 1.46 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

33.5% of Precigen shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 41.4% of Precigen shares are held by insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Precigen has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	273.83	-$250.64M	-$1.04	N/A
Praxis Precision Medicines	$8.55M	1,006.65	-$303.27M	-$12.93	N/A

Precigen currently has a consensus target price of $14.50, suggesting a potential upside of 95.02%. Praxis Precision Medicines has a consensus target price of $585.95, suggesting a potential upside of 90.08%. Given Precigen's higher probable upside, research analysts clearly believe Precigen is more favorable than Praxis Precision Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.95

Summary

Precigen beats Praxis Precision Medicines on 9 of the 17 factors compared between the two stocks.

How does Precigen compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Precigen (NASDAQ:PGEN) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

Precigen has a net margin of -183.98% compared to Kymera Therapeutics' net margin of -285.33%. Precigen's return on equity of 423.75% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.22%	-19.21%
Precigen	-183.98%	423.75%	84.39%

Kymera Therapeutics has a beta of 1.96, meaning that its stock price is 96% more volatile than the broader market. Comparatively, Precigen has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market.

33.5% of Precigen shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by company insiders. Comparatively, 41.4% of Precigen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Kymera Therapeutics currently has a consensus price target of $131.63, indicating a potential upside of 13.20%. Precigen has a consensus price target of $14.50, indicating a potential upside of 95.02%. Given Precigen's higher probable upside, analysts plainly believe Precigen is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.88
Precigen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Precigen has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	246.58	-$311.35M	-$3.24	N/A
Precigen	$9.68M	273.83	-$250.64M	-$1.04	N/A

In the previous week, Kymera Therapeutics had 4 more articles in the media than Precigen. MarketBeat recorded 9 mentions for Kymera Therapeutics and 5 mentions for Precigen. Precigen's average media sentiment score of 1.46 beat Kymera Therapeutics' score of 0.73 indicating that Precigen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Precigen	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Precigen beats Kymera Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Precigen compare to Ionis Pharmaceuticals?

Precigen (NASDAQ:PGEN) and Ionis Pharmaceuticals (NASDAQ:IONS) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

33.5% of Precigen shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 41.4% of Precigen shares are owned by insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Precigen currently has a consensus target price of $14.50, indicating a potential upside of 95.02%. Ionis Pharmaceuticals has a consensus target price of $90.80, indicating a potential upside of 101.66%. Given Ionis Pharmaceuticals' higher probable upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Precigen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73

Precigen has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market.

Precigen has higher earnings, but lower revenue than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	273.83	-$250.64M	-$1.04	N/A
Ionis Pharmaceuticals	$874.09M	8.56	-$381.39M	-$3.46	N/A

In the previous week, Ionis Pharmaceuticals had 8 more articles in the media than Precigen. MarketBeat recorded 13 mentions for Ionis Pharmaceuticals and 5 mentions for Precigen. Precigen's average media sentiment score of 1.46 beat Ionis Pharmaceuticals' score of 0.33 indicating that Precigen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ionis Pharmaceuticals	2 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Ionis Pharmaceuticals has a net margin of -64.76% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-183.98%	423.75%	84.39%
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%

Summary

Precigen beats Ionis Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Precigen compare to Protagonist Therapeutics?

Precigen (NASDAQ:PGEN) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

33.5% of Precigen shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 41.4% of Precigen shares are owned by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Precigen has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market.

In the previous week, Protagonist Therapeutics had 6 more articles in the media than Precigen. MarketBeat recorded 11 mentions for Protagonist Therapeutics and 5 mentions for Precigen. Precigen's average media sentiment score of 1.46 beat Protagonist Therapeutics' score of 0.65 indicating that Precigen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Precigen presently has a consensus price target of $14.50, indicating a potential upside of 95.02%. Protagonist Therapeutics has a consensus price target of $147.13, indicating a potential upside of 3.05%. Given Precigen's higher possible upside, analysts plainly believe Precigen is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89

Protagonist Therapeutics has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	273.83	-$250.64M	-$1.04	N/A
Protagonist Therapeutics	$46.02M	200.77	-$130.15M	$1.03	138.62

Protagonist Therapeutics has a net margin of 29.40% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-183.98%	423.75%	84.39%
Protagonist Therapeutics	29.40%	12.03%	11.23%

Summary

Protagonist Therapeutics beats Precigen on 10 of the 17 factors compared between the two stocks.

Get Precigen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PGEN vs. The Competition

Export

Metric	Precigen	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.65B	$3.83B	$7.19B	$14.89B
Dividend Yield	N/A	3.65%	2.57%	11.71%
P/E Ratio	-7.15	14.27	274.06	25.33
Price / Sales	273.83	1,415.32	697.71	112.26
Price / Cash	N/A	108.94	77.71	51.48
Price / Book	123.92	15.14	10.37	6.24
Net Income	-$250.64M	-$22.78M	$3.49B	$358.55M
7 Day Performance	9.34%	-3.99%	-1.73%	-2.03%
1 Month Performance	21.89%	-2.60%	-1.45%	-4.78%
1 Year Performance	91.13%	37.08%	18.16%	5.46%

Precigen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PGEN Precigen	4.0092 of 5 stars	$7.44 +6.2%	$14.50 +95.0%	+95.0%	$2.65B	$9.68M	N/A	47	Positive News Options Volume
ABVX Abivax	2.4809 of 5 stars	$114.79 flat	$156.50 +36.3%	+24.2%	$10.02B	N/A	N/A	61	Positive News Upcoming Earnings
PRAX Praxis Precision Medicines	3.069 of 5 stars	$351.81 flat	$585.95 +66.6%	+673.5%	$9.82B	$8.55M	N/A	110	Positive News
KYMR Kymera Therapeutics	1.8997 of 5 stars	$117.39 flat	$128.70 +9.6%	+139.3%	$9.76B	$39.21M	N/A	170	Analyst Forecast
IONS Ionis Pharmaceuticals	3.228 of 5 stars	$58.09 flat	$94.20 +62.2%	-22.7%	$9.65B	$944M	N/A	1,402	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PGEN) was last updated on 9/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Precigen (PGEN) Competitors

PGEN vs. ABVX, PRAX, KYMR, IONS, and PTGX

How does Precigen compare to Abivax?

Summary

How does Precigen compare to Praxis Precision Medicines?

Summary

How does Precigen compare to Kymera Therapeutics?

Summary

How does Precigen compare to Ionis Pharmaceuticals?

Summary

How does Precigen compare to Protagonist Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGEN vs. The Competition

Precigen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Precigen (PGEN) Competitors

PGEN vs. ABVX, PRAX, KYMR, IONS, and PTGX

How does Precigen compare to Abivax?

Which has better valuation & earnings, PGEN or ABVX?

Do analysts rate PGEN or ABVX?

Do institutionals and insiders believe in PGEN or ABVX?

Is PGEN or ABVX more profitable?

Which has more risk & volatility, PGEN or ABVX?

Does the media refer more to PGEN or ABVX?

Summary

How does Precigen compare to Praxis Precision Medicines?

Which has more risk and volatility, PGEN or PRAX?

Is PGEN or PRAX more profitable?

Does the media refer more to PGEN or PRAX?

Do institutionals and insiders hold more shares of PGEN or PRAX?

Which has preferable earnings & valuation, PGEN or PRAX?

Do analysts prefer PGEN or PRAX?

Summary

How does Precigen compare to Kymera Therapeutics?

Is KYMR or PGEN more profitable?

Which has more risk and volatility, KYMR or PGEN?

Do institutionals & insiders have more ownership in KYMR or PGEN?

Do analysts rate KYMR or PGEN?

Which has better earnings and valuation, KYMR or PGEN?

Does the media favor KYMR or PGEN?

Summary

How does Precigen compare to Ionis Pharmaceuticals?

Do insiders and institutionals believe in PGEN or IONS?

Do analysts recommend PGEN or IONS?

Which has more risk & volatility, PGEN or IONS?

Which has stronger earnings and valuation, PGEN or IONS?

Does the media refer more to PGEN or IONS?

Is PGEN or IONS more profitable?

Summary

How does Precigen compare to Protagonist Therapeutics?

Do insiders & institutionals believe in PGEN or PTGX?

Which has more volatility & risk, PGEN or PTGX?

Does the media prefer PGEN or PTGX?

Do analysts prefer PGEN or PTGX?

Which has higher valuation and earnings, PGEN or PTGX?

Is PGEN or PTGX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGEN vs. The Competition

Precigen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools